Answers are grounded in this paper and cite their sources.
Experimental evaluation shows 8-nitrotryptanthrin inhibits tumor growth in colorectal cancer, indicating potential for new therapies.
Objective To investigate the anticancer effects and underlying mechanisms of 8-nitrotryptanthrin (8-Nitrotryp) against colorectal cancer (CRC). Methods The effects of 8-Nitrotryp on proliferation, colony formation, and migration were evaluated in HCT116 and SW480 cells, with comparisons to its parent compound tryptanthrin (Tryp). Mitochondrial membrane potential (MMP) was assessed using JC-1 staining, and early apoptosis was analyzed by flow cytometry. Proteomic analysis and Western blotting were employed to examine the modulation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of the rapamycin (mTOR) pathway and transforming growth factor-β (TGF-β)/Sma- and Mad-related proteins (SMAD) signaling pathways, as well as epithelial–mesenchymal transition (EMT). Results 8-Nitrotryp significantly inhibited proliferation of HCT116 (IC 50 = 0.81–1.08 μM; P < 0.001) and SW480 cells (IC 50 = 0.76–1.59 μM; P < 0.001), suppressed colony formation of HCT116 ( P < 0.001 at 1 μM) and SW480 cells ( P < 0.001 at 2 μM), and inhibited migration in a dose-dependent manner (0.5–2 μM), demonstrating greater potency than Tryp. It also suppressed MMP and induced early apoptosis in HCT116 ( P < 0.001 at 1 μM) and SW480 cells ( P < 0.001 at 0.5 μM). Proteomic analysis and Western blotting revealed that 8-Nitrotryp downregulated PI3K expression, inhibited the phosphorylation of AKT and mTOR, and reduced TGF-β1-induced SMAD2 phosphorylation. Additionally, 8-Nitrotryp suppressed the EMT process. Conclusion 8-Nitrotryp inhibits CRC progression by modulating the TGF-β/SMAD and PI3K/AKT/mTOR pathways, highlighting its potential as a multi-target therapeutic agent for CRC and warranting its further investigation. Novelty and Impact CRC is a global health challenge with limited treatments for advanced stages. This study provides the first evidence of 8-Nitrotryp’s antitumor efficacy in CRC, demonstrating its dual inhibitory activity on the TGF-β/SMAD and PI3K/AKT/mTOR pathways. Compared to Tryp, 8-Nitrotryp exhibits markedly enhanced potency, with lower IC 50 values due to the introduction of a nitro group. Furthermore, the suppression of EMT is mechanistically linked to TGF-β/SMAD pathway inhibition. These findings suggest 8-Nitrotryp’s potential as a novel therapeutic for CRC.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: